Lexicon Pharmaceuticals (LXRX) Operating Margin (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Operating Margin of 4.72% for Q1 2026, up 203007.0% year-over-year from N/an in Q1 2025, and up 98.25% on a QoQ basis from 269.07% in Q4 2025.
Lexicon Pharmaceuticals (LXRX) has 16 years of Operating Margin data on file, last reported at 4.72% in Q1 2026.
- Quarterly Operating Margin rose 203007.0% year-over-year to 4.72% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.79% (up 53377.0% YoY) and the FY2025 annual result came in at 98.21%, up 53600.0% from the prior year.
- Operating Margin improved to 4.72% in Q1 2026 per LXRX's latest filing, from 269.07% in the prior quarter.
- Across five years, Operating Margin topped out at 12.94% in Q2 2025 and bottomed at 30636.42% in Q3 2023.
- The 4-year median for Operating Margin is 2697.84% (2024), against an average of 5362.22%.
- The widest annual swing landed in 2024, when Operating Margin soared 2699682 bps; it then slumped 14579 bps in 2025.
- Tracing LXRX's Operating Margin over 4 years: stood at 6101.44% in 2023, then jumped by 98 bps to 123.28% in 2024, then tumbled by 118 bps to 269.07% in 2025, then soared by 98 bps to 4.72% in 2026.
- Per Business Quant, the three latest LXRX Operating Margin figures stand at 4.72% (Q1 2026), 269.07% (Q4 2025), and 85.93% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Lexicon Pharmaceuticals | 872.52 Mn | 701.87 Mn | 20.99 Mn | -4.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.72% |
| Dec 31, 2025 | -269.07% |
| Sep 30, 2025 | -85.93% |
| Jun 30, 2025 | 12.94% |
| Mar 31, 2025 | -2,034.79% |
| Dec 31, 2024 | -123.28% |
| Sep 30, 2024 | -3,639.60% |
| Jun 30, 2024 | -3,360.90% |
| Mar 31, 2024 | -4,147.58% |
| Dec 31, 2023 | -6,101.44% |
| Sep 30, 2023 | -30,636.42% |
| Jun 30, 2023 | -13,955.84% |
| Dec 31, 2021 | 8,919.01% |
| Jun 30, 2021 | -7,674.79% |
| Mar 31, 2021 | -77,181.48% |
| Dec 31, 2020 | 31.38% |
| Jun 30, 2020 | -258,316.00% |
| Mar 31, 2020 | -780.57% |
| Dec 31, 2019 | -541.05% |
| Sep 30, 2019 | 76.30% |
| Jun 30, 2019 | -191.54% |
| Mar 31, 2019 | -716.24% |
| Dec 31, 2018 | -72.44% |
| Sep 30, 2018 | -329.13% |
| Jun 30, 2018 | -219.39% |
| Mar 31, 2018 | -148.63% |
| Dec 31, 2017 | -85.43% |
| Sep 30, 2017 | -103.36% |
| Jun 30, 2017 | -277.08% |
| Mar 31, 2017 | -219.98% |
| Dec 31, 2016 | -136.00% |
| Jun 30, 2016 | -184.28% |
| Mar 31, 2016 | -271.10% |
| Dec 31, 2015 | 69.42% |
| Sep 30, 2015 | -5,950.00% |
| Jun 30, 2015 | -7,097.87% |
| Mar 31, 2015 | -1,480.30% |
| Dec 31, 2014 | -16.05% |
| Sep 30, 2014 | -9,626.73% |
| Jun 30, 2014 | -3,862.57% |
| Mar 31, 2014 | -11,000.72% |
| Dec 31, 2013 | -1,203.97% |
| Sep 30, 2013 | -13,115.97% |
| Jun 30, 2013 | -13,375.70% |
| Mar 31, 2013 | -7,098.61% |
| Dec 31, 2012 | -11,234.86% |
| Sep 30, 2012 | -7,811.83% |
| Jun 30, 2012 | -12,804.02% |
| Mar 31, 2012 | -9,794.33% |
| Dec 31, 2011 | -9,720.70% |
| Sep 30, 2011 | -7,236.90% |
| Jun 30, 2011 | -4,671.35% |
| Mar 31, 2011 | -4,888.59% |
| Dec 31, 2010 | -1,789.70% |
| Sep 30, 2010 | -3,105.38% |
| Jun 30, 2010 | -1,952.47% |